Practical Oncologist Family of Sites
- 2016-06-16 - Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Lower Risk Myelodysplastic Syndromes
- 2016-03-16 - Trial Surprise: Rigosertib May Benefit Some MDS Patients
- 2016-02-16 - Phase 3 Study Demonstrates Aranesp® (Darbepoetin Alfa) Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome (MDS)
- 2015-05-05 - Analysis of Lenalidomide in Patients with Non-Del-5Q MDS Demonstrated Improved Health Related Quality of Life Measures
- 2014-09-10 - Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
- 2014-09-10 - FDA approves InnoPharma's decitabine for injection to treat myelodysplastic syndromes
- 2014-09-10 - Study identifies gene network behind untreatable leukemia and possible treatment target
- 2014-09-10 - Randomized Phase II Clinical Trial Of Pracinostat Set For Front Line Myelodysplastic Syndrome
- 2014-08-25 - Somatic mutations in myelodysplastic syndrome linked to shorter survival after HSCT
- 2014-08-25 - NICE proposes to recommend lenalidomide for myelodysplastic syndromes
- 2014-08-11 - Immunosuppressive drugs increase risk of myeloid disorders among IBD patients
- 2014-07-03 - AG-221 sparked durable responses in hematologic cancers
- 2014-07-03 - BRIEF-GSK announces start of phase III study with eltrombopag in patients with myelodysplastic syndromes
- 2014-06-23 - How I Manage Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome
- 2014-06-23 - Mirati Therapeutics Receives Orphan Drug Designation from U.S. Food & Drug Administration for Mocetinostat in Myelodysplastic Syndrome